These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36759733)
1. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF Ruiz-Saenz A; Atreya CE; Wang C; Pan B; Dreyer CA; Brunen D; Prahallad A; Muñoz DP; Ramms DJ; Burghi V; Spassov DS; Fewings E; Hwang YC; Cowdrey C; Moelders C; Schwarzer C; Wolf DM; Hann B; VandenBerg SR; Shokat K; Moasser MM; Bernards R; Gutkind JS; van 't Veer LJ; Coppé JP Nat Cancer; 2023 Feb; 4(2):240-256. PubMed ID: 36759733 [TBL] [Abstract][Full Text] [Related]
2. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524 [TBL] [Abstract][Full Text] [Related]
3. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344 [TBL] [Abstract][Full Text] [Related]
4. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638 [TBL] [Abstract][Full Text] [Related]
6. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684 [TBL] [Abstract][Full Text] [Related]
7. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314 [TBL] [Abstract][Full Text] [Related]
8. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570 [TBL] [Abstract][Full Text] [Related]
9. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
10. Diverse Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540 [TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239 [TBL] [Abstract][Full Text] [Related]
12. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways. Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228 [TBL] [Abstract][Full Text] [Related]
13. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768 [TBL] [Abstract][Full Text] [Related]
14. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198 [TBL] [Abstract][Full Text] [Related]
15. A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells. Ressa A; Bosdriesz E; de Ligt J; Mainardi S; Maddalo G; Prahallad A; Jager M; de la Fonteijne L; Fitzpatrick M; Groten S; Altelaar AFM; Bernards R; Cuppen E; Wessels L; Heck AJR Mol Cell Proteomics; 2018 Oct; 17(10):1892-1908. PubMed ID: 29970458 [TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767 [TBL] [Abstract][Full Text] [Related]
17. An amino-terminal Tung JK; Neishaboori N; Haraldsdottir S; Suarez CJ Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32669268 [TBL] [Abstract][Full Text] [Related]
18. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer. Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428 [TBL] [Abstract][Full Text] [Related]
19. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642 [TBL] [Abstract][Full Text] [Related]
20. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]